

What is involved?

Over 12 weeks, participants will receive a THC/CBD combination or placebo in the form of an oral, digestible oil. A placebo is designed to look like the treatment being studied but does not have any active ingredients.

There will be in-person and telephone appointments for the participant and study partner. Depending on where participants reside, in-person visits may take place at home or at a facility.

Financial reimbursement for each completed study visit may be available for study participants and their study partners. Please contact your nearest study site for details.

For more information visit LiBBYStudy.org, or contact:

To learn more or to find the nearest study location visit:

LiBBYStudy.org



Scan code with your smartphone's camera or call:

1-800-LiBBY-11
(1-800-542-2911)



Life's end Benefits of cannaBidiol (CBD) and tetrahydrocannabinol (THC)

Led by Alzheimer's disease research experts at the NIH-funded Alzheimer's Clinical Trials Consortium (ACTC).



Life's end Benefits of cannaBidiol (CBD) and tetrahydrocannabinol (THC)

The LiBBY Study

Providing hope for a safe and effective **treatment** at the **end of life** for people with **agitation** related to **dementia**.

Funded by the National Institute on Aging (NIA) of the National Institutes of Health (NIH)

What is the LiBBY Study?

The **Life's-end Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) Study** is the first of its kind to examine **possible benefits** of Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) as a safe treatment **option for hospice-eligible people** with agitation and any type of dementia. The LiBBY Study has **8 to 15 sites** across the United States.

Who is Eligible?

- Adults, age 40 or older
- Dementia diagnosis
- In hospice or hospice eligible
- Experiencing agitation
- Have a study/care partner



End-of-life (EoL) stages for people with dementia are unpredictable but **agitation is a common symptom**. The grieving process can be more difficult when the person who is dying experiences significant agitation. The final stages of dementia may last days, weeks, or months. The LiBBY Study **draws inspiration from Libby Soffar**, who suffered with agitation at the end of her life, and the challenges her family and friends faced in assisting her to die peacefully. Libby's story **speaks to the limited treatment options** for agitation at the end of life and the unpleasant side effects of commonly prescribed medications.

Why use THC and CBD?

The **study treatment** is a combination of THC and CBD as an oil that is taken by mouth. It is being evaluated for **possible benefits in reducing agitation**.

Why test THC and CBD to treat agitation at EoL stages in dementia?

Possible benefits of THC and CBD include reductions in agitation and improvements in caregiver burden caused by commonly prescribed treatments for people at EoL stages.

If THC or CBD use is not legal where a potential participant resides, can they still participate?

Yes. State laws relating to the medical or recreational use of THC or CBD do not apply to use of THC or CBD as part of a research study.

